Novo Nordisk shares rebound as FDA targets illegal drug copies

Core Viewpoint - Shares in Danish drugmaker Novo Nordisk increased by 4.7% in early trading on Friday, recovering some of the steep losses from the previous two sessions after the U.S. Food and Drug Administration (FDA) committed to addressing the mass-marketing of unapproved drugs [1] Group 1 - Novo Nordisk's stock performance showed a recovery of 4.7% in early trading [1] - The recovery followed two sessions of significant losses for the company [1] - The FDA's pledge to tackle the issue of unapproved drug marketing is a key factor influencing the stock movement [1]